Gosset Ownership
Public
Employees
~800
Therapeutic Areas
Stage
Other
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Ionis Pharmaceuticals General Information
Ionis has pioneered antisense oligonucleotide therapeutics with three approved drugs—nusinersen for spinal muscular atrophy, inotersen for hereditary transthyretin amyloidosis, and volanesorsen for familial chylomicronemia syndrome. The company has a robust late-stage pipeline with several pivotal studies ongoing in neurology and cardiology. Recent clinical results include FDA fast-track designation for Zilganersen in Alexander disease and orphan drug designation for Olezarsen in FCS
Contact Information
Drug Pipeline
No pipeline data available
Key Partnerships
Roche, Biogen, AstraZeneca, Novartis, Otsuka Pharmaceutical Co., Bayer AG
Ionis Pharmaceuticals Funding
No funding data available
To view Ionis Pharmaceuticals's complete valuation and funding history, request access »